A5090378419- Neuropeptides and Animal Physiology
- Receptor Mechanisms and Signaling
- Diabetes and associated disorders
- Peptidase Inhibition and Analysis
- Diabetes Management and Research
- Diabetes Treatment and Management
- Pancreatic function and diabetes
- Neurobiology and Insect Physiology Research
- Neuroendocrine regulation and behavior
- Neuroendocrine Tumor Research Advances
- Monoclonal and Polyclonal Antibodies Research
- Macrophage Migration Inhibitory Factor
- Hypothalamic control of reproductive hormones
- Circadian rhythm and melatonin
- Ion Transport and Channel Regulation
- Neuroscience and Neuropharmacology Research
- Cardiovascular, Neuropeptides, and Oxidative Stress Research
- Galectins and Cancer Biology
- Retinoids in leukemia and cellular processes
- Pancreatic and Hepatic Oncology Research
- Apelin-related biomedical research
- Immune Cell Function and Interaction
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Allergic Rhinitis and Sensitization
ImCyse (Belgium)
2023-2024
Novo Nordisk Foundation
2022
University of Copenhagen
2022
Inserm
2003
Université Libre de Bruxelles
1992-2000
IMCY-0098, a synthetic peptide developed to halt disease progression via elimination of key immune cells in the autoimmune cascade, has shown promising safety profile for treatment type 1 diabetes (T1D) recent phase 1b trial. This exploratory analysis data from that trial aimed identify patient biomarkers at baseline associated with positive response and examined associations between parameters clinical efficacy endpoints (as surrogates mechanism action endpoints) using an artificial...
Differential diagnosis of pancreatic cancer and chronic pancreatitis is sometimes difficult cytological examination brushings or aspirated material collected during endoscopic retrograde cholangiopancreatography (ERCP) remains disappointing. As point mutations in codon 12 the c-Ki-ras 2 gene are found most adenocarcinoma not pancreatitis, this study analysed prospectively presence these brushing samples ERCP 45 patients (26 males, 19 females) showing a dominant stricture main duct at...
Abstract Background The INNODIA consortium has established a pan-European infrastructure using validated centres to prospectively evaluate clinical data from individuals with newly diagnosed type 1 diabetes combined centralised collection of samples determine rates decline in beta-cell function and identify novel biomarkers, which could be used for future stratification phase 2 trials. Methods In this context, we have developed Master Protocol, based on the “backbone” natural history study,...
Abstract Background Type 1 diabetes (T1D) is a CD4 + T cell-driven autoimmune disease characterized by the destruction of insulin-producing pancreatic β-cells CD8 cells. Achieving glycemic targets in T1D remains challenging clinical practice; new treatments aim to halt autoimmunity and prolong β-cell survival. IMCY-0098 peptide derived from human proinsulin that contains thiol-disulfide oxidoreductase motif at N-terminus was developed progression promoting specific elimination pathogenic...
Vasoactive intestinal peptide (VIP) is a prominent neuropeptide whose actions are mediated by VPAC receptors belonging to class II G protein-coupled receptors. To identify contact sites between VIP and its VPAC1 receptor, an analog of substituted with photoreactive para-benzoyl-l-Phe (Bpa) at position 22 has been synthesized evaluated in Chinese hamster ovary cells stably expressing the recombinant human receptor. Bpa22-VIP native equipotent stimulating adenylyl cyclase activity cell...
A vasoactive intestinal polypeptide (VIP) analog, acylated on the amino-terminal histidine by hexanoic acid (C<sub>6</sub>-VIP), behaved as a VPAC<sub>2</sub> preferring agonist in binding and functional studies human VIP receptors, radioiodinated C<sub>6</sub>-VIP was suitable ligand for wild-type chimeric receptors. We evaluated properties of C<sub>6</sub>-VIP, its analog AcHis<sup>1</sup>-VIP, VPAC<sub>2</sub>-selective Ro 25-1553 VPAC<sub>1</sub> receptors exchanging different domains...
We analyzed the functional and binding properties of "normal" pituitary adenylate cyclase-activating polypeptide (N-PACAP) type I, PACAP II/vasoactive intestinal peptide (VIP)1, chimeric N-PACAP/VIP1 receptors expressed in Chinese hamster ovary cells. The three were investigated using radioiodinated tracers: 125I-VIP, 125I-PACAP-27, 125I-PACAP-29 (125I-PACAP-27-Gly28,Lys29-amide). tracers labeled very different receptor densities; more than either 125I-VIP or 125I-PACAP-27 cell lines....
A bstract : Vasoactive intestinal polypeptide (VIP) acts through interaction with two subclasses of seven transmembrane G protein‐coupled receptors named VIP 1 and 2 receptors. These have been cloned in different species, such as rat human. Considering the distribution both receptor subclasses, there is considerable interest development selective agonists antagonists. The present study compares binding properties VIP, PACAP, GRF, secretin, helodermin analogues on recombinant human On...
In order to identify the receptor domains responsible for VPAC 1 selectivity of VIP agonist, [Lys15, Arg16, Leu27] (1–7)/GRF (8–27) and antagonist, Ac His1 [D‐Phe2, Lys15, (3–7)/GRF (8–27), we evaluated their binding functional properties on chimeric /VPAC 2 receptors. Our results suggest that N‐terminal extracellular domain is antagonist. Selective recognition agonist was supported by a larger area: in addition domain, first loop, as well additional determinants distal part were involved....
Vasoactive Intestinal Polypeptide (VIP) interacts with a high affinity to two subclasses of G protein coupled receptors named VPAC 1 and 2 , has 3–10 fold preference for over receptors. Selective ligands each receptor subclass were recently described. [R 16 ]‐PACAP (1–23) [L 22 ]‐VIP are selective agonists. Chimaeric human ‐VPAC recombinant expressed in CHO cells used identify the domains implicated these recognition. The (1–27) did not require receptor's NH ‐terminus domain but involved...